A phase II randomized multicenter trial comparing the efficacy of concomitant hormone therapy + short radiotherapy versus radiotherapy alone in the salvage treatment of patients with detectable PSA after radical prostatectomy.

Trial Profile

A phase II randomized multicenter trial comparing the efficacy of concomitant hormone therapy + short radiotherapy versus radiotherapy alone in the salvage treatment of patients with detectable PSA after radical prostatectomy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Degarelix (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms GETUG-AFU22
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 2017 Genitourinary Cancers Symposium
    • 18 Feb 2017 Acute toxicity results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top